| Line Item | 2026-01-31 | Y/Y |
|---|---|---|
| Revenue | $365.0M | +18.2% |
| Cost of Revenue | $38.0M | +22.7% |
| R&D Expense | $212.4M | +229.3% |
| SG&A Expense | $149.1M | +412.6% |
| Pre-tax Income | -$101.2M | -172.7% |
| Income Tax | -$59.2M | -7.2% |
| Net Income | -$42.1M | -121.6% |
| EPS (Basic) | -$0.74 | -114.8% |
| EPS (Diluted) | -$0.76 | -158.0% |
| Line Item | 2026-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $440.8M | +208.6% |
| Accounts Receivable | $33.1M | +13.7% |
| Current Assets | $1.28B | +268.2% |
| Total Assets | $1.42B | +225.3% |
| Current Liabilities | $792.8M | +357.6% |
| Total Liabilities | $801.0M | +315.8% |
| Stockholders' Equity | $614.7M | +3907.6% |
| Line Item | 2026-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $152.2M | +23.6% |
| Investing Cash Flow | -$1.1M | +80.5% |
| Financing Cash Flow | $148.2M | +353.1% |